Table 4 MR-IVW estimates for all phenotypes assumed to be causally affected by apoA-IV concentrations.

From: Evaluating the Causal Relation of ApoA-IV with Disease-Related Traits - A Bidirectional Two-sample Mendelian Randomization Study

Phenotype (outcome)

Causal effect of apoA-IV on phenotype

No. of SNPs

Beta§

95% CI§

P-value

Lipid traits

HDL-C, unadjusted

2

−0.4017

[−0.5970, −0.2064]

5.52e-05

LDL-C, unadjusted

2

0.1931

[−0.0197, 0.4059]

0.0754

TG, unadjusted

2

−0.0761

[−0.2677, 0.1154]

0.4360

Kidney function

eGFR

2

0.0207

[−0.0136, 0.0550]

0.2369

Adiposity-related parameters

BMI

2

−0.0325

[−0.1840, 0.1190]

0.6744

WHR

2

0.0119

[−0.1609, 0.1847]

0.8930

Fasting Glucose

Fasting Glucose

3

0.0462

[−0.0708, 0.1631]

0.4392

  1. §In SD per change in log(apoA-IV) for the lipid and obesity traits, in log(eGFR) per change in log(apoA-IV) for kidney function, in mmol/L per change in log(apoA-IV) for fasting glucose. Here, apoA-IV acts as exposure and the phenotypes as the outcome traits. A p-value smaller than 0.05/8 = 0.00625 is considered to be significant (marked in bold).
Back to article page